• Explore /
  • Poster
  • / Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120).

Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120).

Abstract Poster

Authors

null

Y. Ito

Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan

Y. Ito , K. Aogi , N. Masuda , S. Ohno , T. Oda , H. Iwata , M. Kashiwaba , Y. Fujiwara , S. Kamigaki , T. Ueno , S. Takashima

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - Triple-negative/Cytotoxics/Local Therapy

Track

Breast Cancer

Sub Track

Triple-Negative Breast Cancer

Clinical Trial Registration Number

NCT00467012

Citation

J Clin Oncol 29: 2011 (suppl; abstr 1119)

Abstract #

1119

Poster Bd #

24D

Abstract Disclosures

Similar Posters

First Author: Frederik Marme

First Author: Jianqing Zhu

First Author: Hideaki Bando

First Author: Kathrin Heinrich